Nuvectra (NVTR) Getting Somewhat Positive Media Coverage, Accern Reports
News articles about Nuvectra (NASDAQ:NVTR) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nuvectra earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.2253238776724 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of Nuvectra (NVTR) opened at $9.65 on Tuesday. Nuvectra has a one year low of $5.39 and a one year high of $15.00. The stock has a market cap of $104.07 and a price-to-earnings ratio of -2.05. The company has a current ratio of 2.90, a quick ratio of 2.72 and a debt-to-equity ratio of 0.37.
Nuvectra (NASDAQ:NVTR) last released its earnings results on Wednesday, November 1st. The company reported ($1.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.16) by $0.07. The company had revenue of $7.60 million during the quarter, compared to the consensus estimate of $8.08 million. Nuvectra had a negative net margin of 204.19% and a negative return on equity of 68.63%. The company’s revenue was up 100.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.92) EPS. analysts expect that Nuvectra will post -4.58 earnings per share for the current fiscal year.
Nuvectra Company Profile
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.